Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million...
Lingyi Biotechnology
Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement
China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement...
Lingyi Biotechnology’s Gene Therapy Candidate LY-M001 Gets FDA Green Light for Gaucher’s Disease
Lingyi Biotechnology Co., Ltd, a China-based gene therapy developer, has secured clinical trial approval from...
Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline
China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100...